New approaches for brain repair-from rescue to reprogramming. by Barker, Roger et al.
New approaches for brain repair –  
from rescue to reprogramming 
Roger A Barker1, Magdalena Götz2,3, Malin Parmar4 
 
1 Department of Clinical Neuroscience and Cambridge Stem Cell Institute, University of Cambridge, 
Cambridge CB2 0PY 
2 Institute for Stem Cell Research, Helmholtz Center Munich and Physiological Genomics, Biomedical 
Center, Ludwig-Maximilians University, Großhadernerstr. 9, 82152 Planegg-Martinsried, Germany 
3 SyNergy, Excellence Cluster Systems Neurology, Center for Stroke and Dementia, Feodor-
Lynenstr.17, 81377 Munich, Germany 
4 Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, BMC A11, 
Sölvegatan 17, S-221 84 Lund, Sweden 
 
 
Email: rab46@cam.ac.uk;  Tel: +44 1223 331160;  Fax: +44 1223 331174 
Email: Magdalena.goetz@helmholtz-muenchen.de 
Email: malin.parmar@med.lu.se 
  
Acknowledgements and Funding 
Roger Barker is funded by the NIHR Biomedical Research Centre in Cambridge, Cure PD, PDUK, 
European Research Council under the European Union’s Seventh Framework Programme: FP/2007-
2013 NeuroStemcellRepair (no. 602278). Wellcome Trust MRC Stem Cell Institute and MRC UKRMP 
PSCP. He has received consultancy payment from FCDI and LCT. 
MG is funded by the German research foundation (CRC870, SPP1738, 1757, EXC1010 Synergy), The 
Ministry of Science and Research (MAIV), ERANET and the ERC (ChroNeuroRepair). Patent WO 
2015/114059 A1. 
MP receives funding from the New York Stem Cell Foundation, the European Research Council under 
the European Union’s Seventh Framework Programme: FP/2007-2013 NeuroStemcellRepair (no. 
602278) and ERC Grant Agreement no. 30971, the Swedish Research Council and the Strategic 
Research Area Multipark at Lund University Multipark. MP is a New York Stem Cell foundation 
Robertson Investigator. MP is the owner of Parmar Cells and co-inventor of patent 62/145,467. 
 
We would like to thank Danielle Daft for her help in the preparation of this manuscript.   
PREFACE 
The ability to repair or promote regeneration within the adult human brain has been envisioned for 
decades. However, to date the results have largely been disappointing and typically involved delivery 
of growth factors and cell transplants designed to rescue or replace a specific population of neurons. 
Of late, new approaches using stem cell derived cell products and direct cell reprogramming have 
opened up the possibility of effecting better repair with the reconstruction of neural circuits. In this 
review we briefly summarise the history of neural repair and then discuss these new therapeutic 
approaches especially with respect to chronic neurodegenerative disorders. 
  
INTRODUCTION 
The mammalian central nervous system (CNS), unlike many other organs, has a limited capacity for 
self-repair and our ability to overcome this would transform how we could treat patients with a vast 
array of neurological disorders. However, limited neurogenesis in the adult CNS, the failure of axonal 
regeneration and the non-permissive local environment have been major barriers, literally, for CNS 
repair.  Nevertheless, in recent years it has been shown that much can actually be done in the mature 
CNS to foster innate regeneration.  
Diseases or disorders of the CNS can be developmental, inherited or acquired; acute or chronic and 
each brings with them a different set of challenges when developing repair strategies. Both acute 
damage and chronic neurodegenerative disorders (NDDs) are characterised by an inter-related 
macroglial and microglial/inflammatory reaction with changes in the extracellular matrix and/or 
alterations in the blood brain barrier. Therefore, agents improving this environment could be used to 
help protect neurons from further damage and promote circuit reformation and function. Such 
disease modifying therapies using, for example, trophic factors or cell transplants releasing such 
factors could in theory be used either alone at early stages of disease or combined with approaches 
designed to replace lost cells through either cell transplantation, re-activation of endogenous 
neurogenesis, or directed reprogramming in situ.  In this review we will discuss three main strategies 
for restoring function in the damaged/diseased CNS: 
(i) cell rescue using neurotrophic factors or cell-based approaches that employ putative 
disease modifying effects; 
(ii) cell replacement therapies using transplants of exogenously derived and in vitro cultured 
cells;  
(iii) cell replacement using endogenous neural precursor cells or strategies that involve the 
direct reprogramming of resident cells within the brain. 
FIGURE 1 here 
 
NEUROTROPHIC FACTORS and DISEASE MODIFICATION  
 
Enhancing the regenerative potential of the CNS in the face of a disease process can be done in 2 
major ways. Firstly using approaches that restore and maintain the functional integrity of those cells 
that are dysfunctional but not lost. This typically involves neurotrophic factors, some of which could 
be delivered using cell-based treatments. However grafted cells could also be used to protect 
dysfunctional cells from ongoing insults such as metabolic stress. Alternatively it could be done 
through minimizing environmental barriers to repair, e.g. by modifying the extracellular matrix and/or 
glial/immune reaction (see Adams and Gallo, 20181; Fawcett 20152).  
 
The ability to promote endogenous repair using exercise based therapies as well as cognitive training 
has been shown experimentally to have effects on promoting endogenous neurogenesis and the local 
production of growth factors such as BDNF in the brain3. However, whether these changes seen in 
experimental animals can translate into clinical benefits is largely unknown but such intervention do 
have the potential to be used in combination with cell replacement/rescue therapies to optimise 
reparative benefits.  
 
The use of trophic factors has been explored for over 20 years, most notably in ALS and PD (reviewed 
in Bartus & Johnson, 20164,5). These initial studies suffered from major problems with delivery – the 
factors either failing to reach their neuronal target or being rapidly inactivated. This led to a new round 
of trials with intraparenchymal delivery, most notably with GDNF delivered into the striatum of 
patients with moderately advanced PD. In two open label studies, from 2 independent centres, this 
produced positive clinical responses with post mortem and imaging data supporting its mode of 
action6-9. These results led to a double-blind placebo-controlled trial of 34 patients with PD, which 
found that patients in receipt of GDNF showed no significant benefits at 6 months10.  
 
The reasons for the discordant results from these trials have been discussed extensively (e.g.11), 
including placebo effects, although this would not explain the reported changes on PET imaging and 
at post mortem in patients treated with GDNF infusions. Furthermore, in the double-blind study, the 
group in receipt of saline did not improve which also argues against any placebo effects and suggests 
that the trial failed because the active treatment did not work. This could have been due to the dose 
of GDNF and/or the way it was delivered, both of which were different to those employed in the open 
label studies. Given this uncertainty, further trials have been undertaken including a double-blind 
approach with a new convection enhanced delivery system that better delivers GDNF. However, so 
far positive outcomes have not been achieved (https://scienceofparkinsons.com/2016/07/07/the-
gdnf-trial-bristol-initial-results/) which suggests that the use of trophic factors alone may not work to 
treat such chronic NDDs. This is reinforced by parallel studies delivering other GDNF like factors 12  
including Neurturin using an AAV delivery system (AAV-NTN). Here, the initial open label studies 
showed efficacy but 2 subsequent double-blind placebo control studies (which differed in terms of 
where, and how, the AAV-NTN was delivered) failed to show efficacy13-15.  
 
So, does this mean that repairing the brain with trophic factors is not a viable way forward? This is 
likely to be the case when the disease has advanced beyond a certain stage- namely once you have 
lost a critical number of cells/fibres, it is unrealistic to expect any growth factor to work, as there is 
nothing left for it to regenerate! Given that most NDDs present clinically when there is already 
extensive cell/fibre loss, the early use of these agents will be required- and a post hoc analysis of some 
of the trial data with GDNF and AAV-NTN supports this view14,15. Moreover, the disease state may also 
interfere with growth factor function.  For example GDNF may not be able to act through its normal 
receptor in the presence of alpha synuclein pathology in PD because of alterations in Nurr1 signalling, 
which is needed for this trophic factor to produce its therapeutic effect16. Thus, it may be necessary 
to enhance Nurr1 levels ahead of using GDNF in PD for it to work efficiently, necessitating the adoption 
of combination approaches in any trials going forward. Finally, the optimal dose of any growth factor 
and how to best deliver it, including the volume of distribution needed to maximise its benefits, are 
still major issues to solve. To date, GDNF and AAV-NTN have been delivered in ways that are 
insufficient to cover the structure being treated, and thus many of the failures seen clinically may 
relate to this- for which there is some support from post mortem data relating to both the original 
GDNF and subsequent AAV-NTN studies9,15. 
  
Overcoming environmental hurdles to regeneration 
Promoting neuronal survival and outgrowth is only one aspect of the problem in repairing the CNS. 
The other is enhancing the environment to promote that regenerative process. This essentially distils 
down to modifying the glial elements and/or the ECM, both of which have been reported to provide 
inhibitory signals for repair in the adult CNS1,2. 
 
In terms of the glial cells, it has long been known that astrocytes and oligodendrocytes both express 
cell surface inhibitors to the regenerating axon, although the expression and extent of these varies as 
a function of disease state- e.g. greater with acute traumatic injuries than chronic NDD. This premise 
that glial cells produce inhibitory factors which can be blocked has led to early clinical trials most 
notably using anti-NOGO antibodies in spinal cord injury (http://clinicaltrials.gov/show/NCT 
00406016). However, this concept that the glia are “bad” for CNS repair has been challenged, in that 
the glial scar/reaction to injury or disease involves a heterogeneous collection of cells, which have a 
variety of functions. So, under some conditions the glial response may be beneficial for repair, possibly 
through effects on the inflammatory response to that CNS disease1. Conversely under other 
circumstances, the opposite may occur. For example, it has recently been reported that microglia can 
induce astrocytes to become neurotoxic17. This concept of ‘gliopathy’ is not new and has been 
explored in ALS where transplanted glial cells have been used to better buffer extracellular glutamate 
and by so doing protect motorneurons18,19. Whether such an approach could be used for treating ALS 
clinically is unknown but highlights the potential use of non-neuronal cell transplants to protect the 
neurons subject to disease. 
More recently there has been interest in the ECM of the brain and especially peri-neuronal nets 
(PNNs). These latter structures are unevenly distributed across the brain and spinal cord and appear 
to have many functions during development and in the adult brain including a role in neural plasticity. 
This has been shown to extend to NDDs, most notably in transgenic models of AD, where removing 
PNNs using either Chrondoitinase-ABC (Ch-ABC) or genetically, has been shown to improve cognitive 
function while not influencing the underlying disease process-possibly by enhancing neurite 
outgrowth and synaptic plasticty20,21. All of which suggests that the use of this, or similar, agents may 
have benefits when combined with cell therapies in which synaptic integration with host cells may be 
restricted by local PNNs and/or disease driven increased expression of inhibitory ECM molecules. 
REPLACEMENT THERAPIES USING EXOGENOUS CELLS 
 
When a NDD or injury reaches the point where a critical number of neurons have been lost, the 
replacement of these neurons is essential for functional improvement. This can be done through 
replacing the lost cells by transplantation into single or multiple brain regions to partially recreate 
complex circuits either locally or over long distance as outlined in FIGURE 2. 
 
Figure 2 here 
 
For this to work, a number of important questions need to be addressed. Firstly what is the optimal 
cell type(s) to be transplanted and at what developmental stage should it be harvested for grafting? 
Secondly what CNS location(s) is/are needed for optimal recovery and fibre outgrowth. Thirdly how 
many cells are needed for effective repair and finally should other interventions be done either at the 
same time as grafting or post transplantation to enhance survival, integration or function. 
Cell Replacement Therapy using human fetal allografts  
PD is one of the least complex NDD to target with cell-based therapies given the fact that the local 
degeneration of DAergic neurons in the midbrain is known to be critical to the clinical expression of 
many features of this disorder. It has therefore been the subject of a relatively large number of clinical 
transplantation trials using the developing midbrain dopamine cells derived from the human fetal 
ventral midbrain (VM)22. Although the outcome of these trials has been highly variable23, they have 
shown that at least a sub-group of PD patients in receipt of such transplants from different centers do 
well24-27. However, it has also been shown that over time, a minority of the transplanted cells become 
affected by the disease process and show protein aggregation28,29, and that some patients can 
experience troublesome side effects such as graft induced dyskinesias30-32 relating to graft 
composition and their capacity to innervate the whole putamen22.  
Clinical trials using transplants of primary human fetal striatal tissue have also been performed in HD 
patients33-35 on the premise that in HD the medium spiny neurons (MSN) of the striatum, are the ones 
that are primarily lost36. In this case, the neurons are placed homotopically into the striatum to 
reconstruct basal ganglia circuits. To date the effects seen in patients are modest at best 33-35, with 
evidence for poor graft survival and integration37.  
Other NDDs and CNS disorders have a more complex pathology, involving several cell types and/or 
cells in many regions of the CNS and it is hard to see how these could be treated by fetal tissue 
transplants, although this may be different with stem cells given our ability to differentiate them to a 
wide range of neuronal phenotypes.  
Cell Replacement Therapy using stem cells 
A major challenge for developing any cell replacement therapy is the ability to reliably and robustly 
generate large numbers of relevant cells. Recent developments using human embryonic stem cells 
(hESCs) and induced pluripotent stem cells (iPSCs) has now made this possible38 with clinical trials 
imminent using this approach in PD, for example 39,40.  
Additionally, stem cell derived DA neurons have also been used to better understand graft function, 
innervation and integration in pre-clinical animal models of PD. For example, comparative studies with 
human fetal VM tissue have shown that both hESC and hiPSC-derived DA progenitors are very similar 
to their fetal counterparts41,42 mediating functional recovery with equivalent potency over a similar 
time course43. Coupled with new methodologies for assessing graft function and integration, their 
mechanism of action, as well as their ability to appropriately innervate and integrate into host circuitry 
have also been studied. These studies have shown that DA neurons transplanted to the rat brain can 
innervate correct target structures when placed either locally at the site of action in the striatum or 
back in the midbrain which requires more extensive axonal outgrowth from the cells42,43. Furthermore, 
they not only innervate but integrate into host neuronal circuitry44 with functional recovery 38,45. 
Similarly, transplantation of stem cell derived MSNs have now been shown to survive and function in 
rodent models of striatal degeneration (used to model HD)46-48. 
Another advantage of using stem cells derived transplants is the ability to remove or minimize 
unwanted neuronal subtypes, e.g. serotonergic neurons in PD, that may mediate the graft-induced 
dyskinesias seen with fetal human VM transplants.  Furthermore, the effect of grafting pure 
populations of neurons, or a combination of neuronal and or astrocytic cell types can be compared. 
Indeed deficient astrocyte function may contribute to the loss of neurons in many NDDs and the 
absence of such cells may impact on neuronal survival in the transplant- as has been shown in fetal 
striatal grafts in patients with HD49.  As an alternative to the possible co-grafting with glial cells, other 
agents or biomaterials engineered to express growth factors, immune modulating components or 
similar to provide a supportive and protective microenvironment could be delivered together with the 
neurons and this may even include some form of scaffolds for larger lesions such as stroke 50. 
Genetic modifications or correction of the cells prior to transplantation could also be used to make 
the grafted cells resistant or refractory to the disease pathology. This may be of critical importance 
when the transplants are derived from the patients’ own cells42, or in diseases such as ALS where the 
motor neuron loss is driven in part by astrocytes. However, even unrelated healthy donor cells can be 
affected by proteinopathies in some NDDs, as has been seen in the PD and HD fetal transplant 
trials28,29,51. In these cases, making cells resistant to the disease by removing the normal protein onto 
which the pathological species templates could be favourable. 
Additionally, as genetic engineering tools become more refined, stem cells could be easily modified to 
enhance aspects of their behaviour, such as modifying chemotactic interactions between the grafted 
cells  and their progeny to enhance migration52; making them refractory to the inhibitory cues of the 
glial scar; increasing their innervation potential by enhanced expression of polysialic acid 53 (all of 
which would need to done so that the enhanced outgrowth is targeted specifically to the area for 
repair) and/or decreasing their immunogenicity54,55. Based on cell transplants in animal models, the 
possibility of engineering stem cell progeny so that their function can be modified using opto- and 
chemogenetic interventions is now also being considered 45,56,57.  
Cell Replacement therapy for circuit reconstruction 
Due to the complexity of the organization of the cerebral cortex, replacement of lost neurons is a more 
challenging task, and is thus still at the pre-clinical stage. New technologies for studying cell integration 
and function have shown that transplanted cells mature, integrate into local host circuitry, form 
functional synapses, mediate recovery and provide circuit repair in animal models of AD, stroke and 
cortical lesions58-62. Importantly, it has recently been shown that the exact brain-wide input 
connectome of neurons in the murine visual cortex can be replicated by transplanted neurons59. This 
is important as aberrant connectivity could lead to deleterious consequences such as epileptic 
seizures. Thus, the adult mammalian brain is more plastic than previously thought in terms of 
accommodating new neurons and building new functional circuitry.   
 
REPLACEMENT THERAPIES USING ENDOGENOUS CELLS 
 
FIGURE 3  here 
 
 
Brain repair from endogenous sources has been considered for some time63, especially after the (re-) 
discovery of adult neurogenesis and proof for its existence in the human brain64,65, prompting 
attempts for recruitment of new neurons from endogenous neurogenic niches to achieve repair in the 
injured brain66,67 (Figure 3). Simply recruiting new neurons from active neurogenic sites appears 
intuitively to be the most promising and easiest to achieve. However, in most cases, the subtypes of 
neurons needed for repair are different from those endogenously generated. Hence, attempts to 
recruit neuroblasts to form neurons at other sites met with only limited success, with many of the 
neuroblasts streaming to the injury site but then failing to fully differentiate into appropriate neuronal 
types which can survive long term67,68 (Figure 3). However, adult neurogenesis is very species-specific69 
and endogenous striatal neurogenesis that has been said to occur in the human (but not rodent)70,71 
brain may prove useful and more easily manipulated to generate the relevant neuronal subtypes lost 
in the striatum after stroke or in NDD72,73.  
A further approach to minimize neuronal loss or help repair and replacement is through the 
recruitment of stem cell derived astrocytes. These differ from the local parenchymal astrocytes and 
release an array of beneficial growth factors74. However, to what extent this also occurs in human 
patients and can be used for therapy is currently unknown.  
Excitingly, the approach to turn these or other parenchymal glial cells into functional neurons by 
forced expression of neurogenic fate determinants has come a long way surprisingly fast. This was 
first tested in 2002 in the nervous system, by turning glial cells into neurons in a dish75. The first 
attempts to achieve this in an injured brain in vivo in 2005 were exciting as proof-of-principle 
experiments, but disappointing in terms of quantitative outcome76,77,78. This has been overcome more 
recently 79-81, and there is now encouraging data on fate conversion of local non-neuronal cells towards 
the neuronal phenotype of the sort affected by the disease process. 
 
A single neurogenic transcription factor (acting also as potent fate determinant in development) can 
in many cases be sufficient to convert glial cells into fully functional neurons82. For example, 
Neurogenin2 or NeuroD1 can yield glutamatergic neurons from proliferating glial cells in the adult 
cerebral cortex including in the highly inflamed brain environment found after TBI79,83,84.  The key to 
generating highly efficient neuronal conversion protocols is not necessarily to add more transcription 
factors, but rather to keep the induced neurons alive by protecting them from death and promoting 
their maturation. Many neurons induced by direct reprogramming from glial cells die because of the 
local generation of excessive reactive oxygen species (ROS) – in a process known as ferroptosis 79,84. 
By keeping the new neurons alive and reducing ROS levels, efficiencies of over 90% have been 
achieved, with almost all glial cells, transduced with the neurogenic transcription factor, acquiring a 
neuronal identity within 1-3 weeks84. Importantly, these neurons also acquired a pyramidal neuronal 
morphology with the identity of deep layer neurons at least at the transcriptional level. Also in other 
brain regions, this approach has been promising including in the minimally injured striatum using Sox2 
and growth factor treatment, the midbrain and the spinal cord85 and in the cerebral cortex using 
NeuroD1 and an amyloid plaque deposition model83. In these latter approaches, a mix of glutamatergic 
or GABAergic neurons has been obtained which may be beneficial if several types of neurons need to 
be replaced or synaptic plasticity increased by providing new GABAergic interneurons as shown 
through transplantation studies86,87. Importantly, synaptic plasticity and new circuit formation using 
these approaches could also be further promoted by co-administering rehabilitation therapies (see 
above).   
The promising outcome of direct reprogramming approaches raises two important issues, namely 
which glial cells to best target and which vectors to use. Targeting proliferating glial cells has obvious 
advantages 88, but they are heterogeneous 1,76,89. Specific targeting of glial subtypes has been achieved 
using subtype-specific promoters driving either directly the reprogramming factors83,90,91 or cell type 
specific Cre expression in transgenic mice80,81,85. Excitingly, this approach has now been shown to work 
with adeno-associated viral vectors (AAVs) that not only have been used in patients clinically but also 
can preferentially infect glial cells92-94. AAVs have been used to reprogram oligodendrocyte progenitor 
cells80,95 to a fate that is dependent on the transcription factor combination- e.g. generating fast 
spiking parvalbumin+ interneurons in the intact striatum95. Moreover, these neurons have been 
shown to receive input from local interneurons80. Finally, recent evidence suggests that striatal and 
midbrain astrocytes and NG2 glia can be converted to neurons with functional GABAergic and DAergic 
like phenotypes in a dopamine depletion model96. While these pioneering studies show that newly 
induced neurons can connect locally and result in behavioural changes, their long-distance input and 
output and contribution to the neuronal network still remains to be explored.  
 Thus, direct neuronal reprogramming in the adult brain has come a long way in the last few years, but 
the question still remains as to how these exciting new approaches will translate to the clinic. While 
there are no major obstacles in turning adult human cells into functioning subtype-specific neurons, 
as has been shown for example with fibroblasts or pericytes in vitro97-100, neuronal reprogramming in 
vivo in the diseased brain has proven more challenging79. Thus, investigating differences in the starting 
cell that affects the outcome of neuronal reprogramming as well as the influences in the local (disease) 
environment is one of the next tasks to further this approach79. Moreover, tools need to be developed 
for non-invasive reprogramming techniques, either using systemic application of viral vectors as is the 
case for some AAVs92-94 or using small molecules that have been shown to be efficient in direct 
neuronal reprogramming in the dish79,101. 
Direct reprogramming also brings new standards to the field as it is important to compare the induced 
cell type to the endogenous counterpart that is being replaced or instructed (e.g. iPSCs to ESCs). This 
can be done using functional assessments and genome-wide expression analysis. This is urgently 
needed for the field of neuronal replacement, as it is so far unknown how authentic the transplanted 
or reprogrammed neurons really are, compared to their endogenous counterpart. Raising these 
standards in basic research and then translating them to the clinic will be the challenge of the future.  
CONCLUSION AND FUTURE PERSPECTIVES 
 
A broad research approach will be needed to deliver effective repair strategies to the human brain 
that combine established approaches with new technologies, and ultimately combined treatment 
strategies. This will only be possible if we both better understand disease states and the contribution 
of all cells and the ECM to the process of damage and cell loss, as well as the innate regenerative ability 
of the adult brain and its capacity to be reprogrammed. By combining approaches to optimize the 
disease environment and synaptic plasticity while providing new neurons for replacement therapy, 
new circuits could be rebuilt with functional benefits across a range of disorders eventually developing 
into a more standard way by which to treat patients. However, this will need to be an iterative 
approach with an ongoing dialogue between preclinical work and clinical trials, and at the same time 
avoiding the temptation to short circuit this approach, with premature claims and commercialisation, 
all of which has the potential to derail this whole field. 
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TABLE 1; CLINICAL TRIALS USING CELL THERAPIES OR GROWTH FACTORS IN PATIENTS WITH 
DIFFERENT NEURODEGENERATIVE DISORDERS (NDDS) 
 
NEURODEGENRATIVE DISEASE 
STATE 
USE OF NEUROTROPHIC 
FACTORS IN CLINCIAL TRIALS 
USE OF CELL TRANSPLANTS IN 
CLINCIAL TRIALS 
ALZHEIMERS DISEASE YES 
 NGF 
NO 
PARKINSON’S DISEASE YES 
 NGF 
 GDNF/NTN 
YES 
 Human fetal VM tissue 
 Adrenal medulla 
 Carotid body 
 Retinal pigmentary 
epithelial cells 
(Spheramine ®) 
ALS YES 
 CNTF 
 BDNF 
 IGF1 
ONGOING 
 [NPC delivering GDNF) 
HUNTINGTON’S DISEASE YES 
 CNTF 
YES 
 Human fetal striatal 
tissue 
OTHER   
 
 
  
FIGURE 1 STRATEGIES TO REPAIR THE DISEASED BRAIN 
 In the healthy brain, the neurons project and synapse with target neurons. These axons are 
supported by myelinating oligodendrocytes and the astrocytes which form a syncytium that helps 
protect neurons and maintain the blood brain barrier (BBB). In disease states, such as that seen with 
NDDs, the neurons become dysfunctional and then die and this is often accompanied with a glial 
reaction and a change in the ECM. Treatments to thus repair and restore the brain in such conditions 
could include: (i) rescuing cells using neurotrophic factors;  (ii) cell transplants to replace lost cells or  
support those targeted by the disease process; (iii) recruitment of endogenous cells to replace those 
lost to the disease process; (iv) modify the glial/inflammatory response and/or (v)modify the ECM 
including peri-neuronal nets. 
FIGURE 2; CELL TRANSPLANT STRATEGIES 
Cell grafts can be used to; 
(i) replace lost cells and/or release factors locally so that they work in a paracrine fashion; 
(ii) support neurons by improving the milieu around them, typically glial transplants; 
(iii) repair local networks through short axonal projections in target structures; 
(iv) repair long distance networks through long axonal projections to structures connected 
to the grafted target; 
(v) to provide a substrate for axonal growth to promote repair. 
Typically transplants being used to repair long distance projecting networks are placed 
homotopically whilst those designed to repair local networks are more likely to be heterotopically 
placed. 
FIGURE 3; STRATEGIES FOR IN SITU REPAIR  
This can be done through the; (a) recruitment of new neurons from endogeneous precursors 
originating from sites of adult neurogenesis or alternatively (b) through directed reprogramming of 
resident non-neuronal, glial cells  
 
